Grifols S.A. (GRFS) vs GSK (GSK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GSK (GSK) has outperformed Grifols S.A. (GRFS) over the past year, gaining 7.4% versus a loss of 23.1%. Over five years, GSK leads with a +19.3% price change compared with -47.9% for GRFS. GSK is the larger company by market cap ($93.24 billion vs $5.04 billion), about 18.5 times the size.
On valuation, Grifols S.A. trades at a lower forward P/E (5.1x vs 9.4x for GSK). GSK pays a dividend yielding 1.46%, while Grifols S.A. does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRFS | GSK |
|---|---|---|
| Share price | $7.41 | $46.54 |
| Market cap | $5.04B | $93.24B |
| 1-day change | -1.20% | -1.02% |
| YTD return | -20.75% | -5.10% |
| 1-year return | -23.05% | +7.36% |
| 5-year return | -47.89% | +19.30% |
| P/E ratio (TTM) | 9.62 | 14.68 |
| Forward P/E | 5.14 | 9.42 |
| EPS (TTM) | $0.77 | $3.17 |
| Dividend yield | 1.43% | 1.46% |
| Annual dividend | $0.00 | $0.68 |
| 52-week high | $9.90 | $61.70 |
| 52-week low | $6.96 | $42.85 |
| Distance from 52-week high | -25.15% | -24.57% |
| Analyst consensus | none | hold |
| Avg. price target upside | +46.69% | +27.48% |
| Average volume | 580.72K | 3.85M |
| Shares outstanding | 258.22M | 2.00B |
| Employees | 25,258 | 66,841 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GSK is about 18.5 times larger than Grifols S.A. by market value ($93.24B vs $5.04B).
- GSK has outperformed GRFS by 30.4 percentage points over the past year.
- GSK trades at a higher earnings multiple (14.7x vs 9.6x trailing P/E).
About Grifols S.A.
GRFS stock →Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
Health Care · Biotechnology: Pharmaceutical Preparations · 25,258 employees
About GSK
GSK stock →GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 66,841 employees
GRFS vs GSK FAQ
Which is bigger, Grifols S.A. or GSK?
GSK (GSK) is larger, with a market capitalization of $93.24B compared with $5.04B for Grifols S.A. (GRFS).
Which stock has performed better over the past year, GRFS or GSK?
GSK returned +7.36% over the past 12 months, compared with -23.05% for GRFS (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, GRFS or GSK?
GRFS has the lower trailing P/E at 9.6, versus 14.7 for GSK. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Grifols S.A. or GSK?
GSK has the higher yield at 1.46%, compared with 1.43% for Grifols S.A..
Are Grifols S.A. and GSK in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.